Supermolecule TGF6™ – Our Innovative New Formula for Absolute Articular Rejuvenation

TGF6™ – What does it do?

Core Functions: ‍Anti-inflammatory – Analgesic – Cartilage Regeneration

TGF-6®, is unique; its effectiveness, especially in the field of reducing joint pain, attributable to the complex of molecules it contains and which make up the musculoskeletal and joint tissues and structures, has been demonstrated in various scientific studies.

Several studies have found that the egg membrane extract increases the synthesis of type III collagen in the fibroblasts of the skin, increasing the softness of the skin itself. Furthermore, the intake of TGF-6 increases the protection of the skin from sunburn caused by UV rays. There are also beneficial effects on hair and nails.

In addition to animal models, the body of evidence has been obtained in clinical studies both on elderly volunteers, mostly suffering from osteoarthritis, and on athletes exposed to high levels of physical stress and wear and tear of the musculoskeletal system and has allowed us to observe particularly rapid and significant effects.

The components of TGF-6 have also been tested in the treatment of inflammatory osteoarticular pathologies of small animals (dogs and cats) managing to obtain a significant reduction in pain and an improvement in the functionality of the joints.

‍

‍

TGF6™ – Ingredient Science

TGF6™ comprises over 500 molecules intelligently working in synergy to comprehensively rejuvenate co-factors in articular wellbeing specifically joints, cartilage, tendons and ligaments. We won't bore you too much with all 500 but here let us breakdown the heavy lifters:

Collagen

Collagen present in TGF6™ is mainly type I collagen, which is the type required by the vascular system, skin, tendons, ligaments, cartilage and bones. It is synthesized during wound healing processes. Type I collagen is more assimilable and digestible than type II, activates the synthesis of hyaluronic acid and endogenous collagen in the cartilage and where necessary.

Hyaluronic Acid

its presence is essential in the skin and cartilage of the joints. It is a key substance in healing skin lesions and lubricating joints.

Chondroitin Sulphate

It has a protective action on the cartilage, synovial membranes and subchondral portions of the bones, i.e. the three structures most damaged by arthritis. It also seems able to counteract some pro-inflammatory factors.

Glucosamine

Plays a major role in maintaining the integrity of cartilage, activates collagen synthesis, reduces the progression of arthritis and related symptoms.

Lysozyme

Lysozyme is an enzyme with antibacterial actions and a powerful immune system activator. It is essential to reactivate the immune system after immunosuppressive therapies and to modulate it in case of autoimmune diseases (such as rheumatoid arthritis, lupus erythematosus, etc.)

Elastin

Elastin is an elastic protein, constituting the connective tissue and which allows many tissues of the body to return to their original shape after being subjected to stretching or contraction forces. Elastin is a fundamental constituent of the skin, giving it the characteristic elastic response when the tissue is subjected to mechanical tension.

β-Growth factor

β-Growth factor is a cytokine with a regulatory action. At the cellular level it controls various processes such as proliferation, cell survival, migration and cell differentiation. It plays a fundamental role in the regulation of the immune system, in tissue regeneration and in embryogenesis.

Bromelain

Bromelain is an enzyme found in the juice and especially the stem of pineapples, it is believed that bromelain can help fight the pain and swelling associated with inflammation. It also appears to interfere with the growth of cancer cells and blood clotting. For this reason, its intake is proposed to reduce inflammation, slow down coagulation, prevent tumors and fight arthritis and other rheumatic disorders. 

Boswellia

Various properties are attributed to boswellia, in particular, anti-inflammatory and anticancer. The anti-inflammatory action ascribed to boswellia appears to be exercised by the boswellic acid contained in the resin extracted from the same plant which is used in the treatment of rheumatism, arthritis, osteoarthritis and muscle pain.

Ascorbic Acid

Ascorbic acid improves the immune system by making leukocytes more active, stimulating the production of interferon (a molecule that allows immune cells to communicate with each other) and therefore regulating inflammatory processes, but also protecting the mucous membranes and joints, it is essential for the formation of collagen present in the epidermal and articular tissues. Collagen is a protein that forms large chains that intertwine to form a very resistant fiber. Reduction of collagen synthesis and loss of reactivity to growth factors are well known phenomena in cells. Ascorbic acid and some cytokines are important regulators of collagen synthesis in all tissues.

MSM

The nutraceutical properties of methylsulfonylmethane derive from its sulfur content in a bioavailable form, thanks to the presence of an organic component which facilitates its absorption. Sulfur is an essential component of living cells and represents the seventh or eighth most abundant element in the human body in terms of weight, comparable in this sense to potassium and slightly more abundant than sodium and chlorine.

TGF6™ – Clinical Evidence

The formulation based on a proprietary matrix, is unique; its effectiveness, especially in the field of reduction of joint pain, attributable to the complex of molecules it contains and which make up the musculoskeletal and joint tissues and structures, has been demonstrated in various scientific studies. In addition to animal models, the body of evidence has been obtained in clinical studies both in elderly volunteers, mostly suffering from osteoarthritis, and in athletes exposed to high levels of physical stress and wear and tear of the musculoskeletal system and has allowed us to observe particularly rapid and significant effects, so as to grant this proprietary matrix the granting of official health claims in Canada. 

‍

Study 1 – Joint pain

‍A first pilot study was conducted on a total of 60 volunteers, including 15 runners, 15 CrossFit practitioners and 30 sedentary people , all presenting chronic joint pain. The subjects took 300 mg of Ovomet® daily for a period of 30 days (CrossFitters) or 50 days (for the other two categories). Parameters such as joint pain, stiffness and function were assessed at baseline and then every 10 days using WOMAC and DASH validated questionnaires; at the end of the treatment periods, the scores of pain stiffness and function improved by an average of 53%, 52% and 46% respectively. 

‍

Study 2 – Osteoarthritis in elderly patients

Another pilot study was conducted on 20 elderly subjects (mean age 73.5 years) suffering from osteoarthritis (assessed by WOMAC index) with acute pain; in this case the evolution of joint function and pain was evaluated during and following a period of administration of 300 mg/day of Ovomet for 50 days. From the very first days, a significant reduction in pain and the extent of joint stiffness was observed based on the WOMAC self-assessment on 3 scales for pain, dysfunction and stiffness. At t0 the pain was classified as very acute on average (13.4 points out of 20); the index decreased significantly starting on day 20, reaching the minimum on day 50 (36% reduction). Stiffness also underwent a decrease, starting from 10% (day 10) up to the maximum reduction of 58% on day 50 (also confirmed by in-person visit during the follow up); while the feature score improved by 32%. Half of the subjects at day 20 and 70% at day 50 reported a significant reduction (quantified as at least -20%) in overall pain, indicating widespread efficacy in the study population. The overall improvement in the condition of the joints was also observed in the decrease in the mean overall WOMAC score which at the beginning of the study was 78.5 points ± 1.79 and decreased to 50.9 ± 2.63 after 50 days (-35.2%). They were subsequently carried out two further studies who integrated the joint condition assessment questionnaires with objective ultrasound measurements of the state of the tendons, especially the Achilles tendon; these new studies were conducted in placebo-controlled mode.  

Study 3 – Controlled, elderly osteoarthritis in nursing home 

The former, in an aging population, enrolled a total of 38 elderly patients in a nursing home (mean age 85 years), 19 of whom took the usual dose of 300 mg/day of Ovomet® for 50 days, while the other half received an indistinguishable placebo. The WOMAC questionnaire revealed a 40% reduction in joint condition score (P=0.04) in treated subjects compared to baseline, versus a non-significant 28% reduction in the placebo group. The ultrasound analysis of the Achilles tendon hardness on a sample of subjects under treatment (n=5) compared to placebo (n=3) showed encouraging results as an improvement in the order of 46% was observed in the treated subjects of the linear stiffness parameter, against a slight worsening (-2.4%) in the placebo arm. 

‍

Study 4 – Controlled, athletes with joint pain 

In the second study the same dosage of 300 mg of Ovomet® was administered to one population of 22 Crossfit athletes to once again evaluate the effects on subjective pain and biomechanical parameters. Intense physical activity(as in the case of crossfit practiced by the volunteers of this study, with almost 8 hours per week on average) is often cause of acute injuries and conditions of weakening, pain and joint, skeletal and muscular dysfunction. These problems can be overcome with suitable training and nutrition practices but also through the administration of active substances such as collagen, glycoproteins and proteoglycans which support the health and correct physiology of joints and tendons/ligaments. 

Administration of Ovomet® in athletes improved the self-assessment score according to WOMAC questionnaire in the treated group (improvement of 62% ± 16.5%), effect found to be smaller in the placebo group (33% ± 16%). Treatment with Ovomet® also made it possible to maintain the linear hardness of the Achilles tendon measured by ultrasound in comparison with what occurred in the placebo group, i.e. a reduction of 37.5%. 

‍

Study 5 – Controlled, short-term efficacy 

A final study, in this case on a population with confirmed osteoarthritic disorders, was conducted for evaluate the efficacy of Ovomet® in a focused way on the short-term effect still in the containment of joint pain. The study was completed by 18 volunteers, 10 of whom took Ovomet®, compared to 8 who took the placebo; analysis tool was the previously mentioned WOMAC validated questionnaire. The uniqueness of this study compared to the previous ones is that the evaluation measured improvements in the pain parameter starting from the third day of treatment (6%), observing already significant results compared to the baseline, the extent of which further increased on day 5 (16%) and then progressively up to day 30 ( 52%), end of the study. The improvement in joint pain was significant both compared to baseline and compared to placebo treatment, which did not produce appreciable changes. Comparable effects were recorded on the WOMAC Joint Dysfunction Scale and WOMAC Overall Score. The study therefore made it possible to verify, in addition to the efficacy of Ovomet®, also the rapidity of its effect, also contributing to the obtainment of specific health claims for Canada.